(1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane | 200433-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane
• 英文别名: (1R,2S)-1-(4,5-diphenyl-1,3-oxazol-2-yl)cyclohexane-1,2-diol
• CAS: 200433-00-7
• 化学式: C₂₁H₂₁NO₃
• 分子量: 335.403
• InChiKey: GJMCHDYCWGDGTP-LAUBAEHRSA-N

物化性质

• 沸点：
  492.0±45.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane 在 原乙酸三甲酯 、 对甲苯磺酸 、 乙酰溴 、 potassium carbonate 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 以83%的产率得到(1R,2S)-1-(4,5-diphenyl-oxazol-2-yl)-1,2-epoxycyclohexane
  参考文献：
  名称：

  A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic

  摘要：

  Synthetic method of novel prostaglandin (PG) mimetic: FR181175 without PG skeleton are described. The key to success is creation of a chiral epoxide using Sharpless AD reaction with high ee yield. FR181157 shows high potency and agonist efficacy at the IP receptor and has good bioavailability. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.054
• 作为产物：
  描述：

  1-(4,5-diphenyloxazol-2-yl)-1-cyclohexene 在 AD-mix-α 作用下， 以 叔丁醇 为溶剂， 以80%的产率得到(1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane
  参考文献：
  名称：

  A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic

  摘要：

  Synthetic method of novel prostaglandin (PG) mimetic: FR181175 without PG skeleton are described. The key to success is creation of a chiral epoxide using Sharpless AD reaction with high ee yield. FR181157 shows high potency and agonist efficacy at the IP receptor and has good bioavailability. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.054

文献信息

• Oxazole compounds useful as PGE2 agonists and antagonists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06245790B1

  公开（公告）日：2001-06-12

  Azole compounds of the formula: wherein R1 is lower alkyl substituted with carboxy, etc., R2 is hydrogen or lower alkyl, R3 is aryl, etc. R4 is aryl, etc. Q is  etc., and X is O, NH or S, and its salt, which are useful as medicament.

  Azole化合物具有以下公式： 其中R1是取代有羧基的低级烷基等， R2是氢或低级烷基， R3是芳基等。 R4是芳基等。 Q是  等，以及 X是O，NH或S， 及其盐，可用作药物。
• Oxazole compounds as prostaglandin e2 agonists or antagonists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06437146B1

  公开（公告）日：2002-08-20

  Oxazole compounds of formula (I), wherein R1 is aryl which may be substituted with halogen(s), R2 is aryl which may be substituted with halogen(s), X is single bond, (a) or SO2, R3 and R4 are independently hydrogen or suitable substituent, (wherein X is (a), neither R3 nor R4 is hydrogen), R3 and R4 may be linked together to form (b), (b) is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s), R5 is hydrogen, etc., A1 is lower alkylene or single bond, (c) is cyclo(C3-C9)alkane or cyclo(C5-C9)alkene, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof, which are useful as medicament.

  式(I)的噁唑化合物，其中R1是芳基，可以用卤素取代，R2是芳基，可以用卤素取代，X是单键，(a)或SO2，R3和R4分别是氢或适当的取代基，(其中X为(a)，R3和R4均不为氢)，R3和R4可以连接形成(b)，(b)是含氮杂环基团，可以用一个或多个适当的取代基取代，R5是氢等，A1是较低的烷基或单键，(c)是环(C3-C9)烷基或环(C5-C9)烯基，或其前药或其药物可接受的盐，可用作药物。
• US6245790B1
  申请人：——

  公开号：US6245790B1

  公开（公告）日：2001-06-12
• US6437146B1
  申请人：——

  公开号：US6437146B1

  公开（公告）日：2002-08-20